Trial record 1 of 1 for:    AT1001-012
Previous Study | Return to List | Next Study

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01218659
Recruitment Status : Completed
First Posted : October 11, 2010
Last Update Posted : July 20, 2015
Information provided by (Responsible Party):
Amicus Therapeutics

Brief Summary:
Study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in male and female patients with Fabry disease who are currently receiving ERT and who have AT1001-responsive GLA mutations.

Condition or disease Intervention/treatment Phase
Fabry Disease Drug: migalastat hydrochloride Biological: agalsidase Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT
Study Start Date : December 2010
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Enzyme Replacement Therapy Biological: agalsidase
intravenous infusion in accordance with the local approved product labeling
Other Names:
  • agalsidase beta; Fabrazyme
  • agalsidase alpha; Replagal

Experimental: AT1001 Drug: migalastat hydrochloride
oral AT1001 capsules and inactive reminder capsules taken every day
Other Name: AT1001

Primary Outcome Measures :
  1. renal function assessed by iohexol Glomerular Filtration Rate (GFR) [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. renal function (assessed by estimated GFR and 24-hour urine protein) [ Time Frame: 18 months ]
  2. composite clinical outcome (assessed by time to occurrence of renal, cardiac, cerebrovascular events or death) [ Time Frame: 18 months ]
  3. cardiac function (assessed by echocardiography) [ Time Frame: 18 months ]
  4. patient reported outcomes (pain and quality of life) [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years to 74 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female between the ages of 16 and 74 diagnosed with Fabry disease
  • Confirmed GLA mutation that has shown to be responsive to AT1001 in vitro
  • Subject has been on ERT for at least 12 months before Visit 2
  • Dose level and regimen of ERT have been stable for 3 months before Visit 2 and is at least 80% of the currently labeled dose and regimen for this time period
  • GFR ≥ 30mL/min/1.73 m2
  • Subjects taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) must be on a stable dose for at least 4 weeks before Visit 1
  • Women who can become pregnant and all men agree to be sexually abstinent or use medically accepted methods of birth control throughout the duration of the study and for up to 30 days after last dose of study medication

    * For sites in Italy: Women who can become pregnant and all men, agree to plan (or have their partner plan) with his/her physician a birth control strategy (or method) in order to avoid pregnancy throughout the duration of the study and for up to 30 days after the last dose of study medication

  • Subject is willing and able to provide written informed consent and assent if applicable

Exclusion Criteria:

  • Subject has undergone, or is scheduled to undergo, kidney transplantation or any other solid organ transplantation
  • Subject is on regular dialysis that is specifically for the treatment of chronic kidney disease
  • Subject has had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 3 months before Visit 1
  • Subject has clinically significant unstable cardiac disease in the opinion of the investigator (e.g., cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure)
  • Pregnant or breast-feeding
  • History of allergy or sensitivity to study medication (including excipients) or other iminosugars (e.g., miglustat, miglitol)
  • Subject has absolute contraindication to iohexol and/or inability to undergo iohexol GFR testing
  • Subject requires treatment with Glyset® (miglitol), or Zavesca® (miglustat)
  • Subject received any investigational/experimental drug, biologic or device within 30 days of Visit 1
  • Any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator that the subject may have an unacceptable risk by participating in this study
  • Otherwise unsuitable for the study, in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01218659

  Hide Study Locations
United States, California
University of California San Diego
La Jolla, California, United States, 92093
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Colorado
University of Colorado Health Sciences Center
Aurora, Colorado, United States, 80045
United States, Georgia
Emory University
Decatur, Georgia, United States, 30033
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66150
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21282
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
Infusion Associates, NE
Grand Rapids, Michigan, United States, 49525
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
NYU School of Medicine, Neurogenetics Unit
New York, New York, United States, 10016
United States, Ohio
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States, 45299
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Virginia
O & O Alpan LLC
Springfield, Virginia, United States, 22152
United States, Wisconsin
Children's Hospital of Wisconsin, Genetics Center
Milwaukee, Wisconsin, United States, 53226
Ciperca SRL
San Fernando del Valle de Catamarca, Catamarca, Argentina, 4700
Instituto de Nefrologia Pergamino SRL
Pergamino, Argentina, B2701XAE
Royal Melbourne Hospital
Parkville, Australia, 3065
Royal Perth Hospital
Perth, Australia, 6000
Medical University of Vienna
Vienna, Austria, 1090
Universitair Ziekenhuis Antwerpen, Konigin Paola Kinderziekenhuis
Antwerpen, Belgium, 2020
Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil, 90035-003
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
Sao Paulo, Brazil, 14048-900
Copenhagen, Denmark, 2100
Hopital Pellegrin
Bordeaux, France, 33076
Hôpital Raymond Poincaré
Garches, France
Hopital Calude Huriez
Lille, France, 59037
Children's Hospital, University Medical Center
Langenbeckstr. A, Mainz, Germany, 55121
Azienda Ospedaliera Universitaria Careggi
Firenze, Italy, 50129
Policlinico Universitario Agostino Gemelli
Roma, Italy, 00168
Niigata University Medical and Dental Hospital
Chuo-ku, Niigata, Japan, 951-8520
Osaka City University Hospital
Abeno-ku, Osaka City, Japan, 545-8586,27
Osaka University Hospital
Suita-shi, Osaka, Japan, 565-0871,27
Jikei University Hospital
Nishi, Tokyo, Japan, 105-8471
University Hospital of Zurich
Zurich, Switzerland, 8091
Gazi University Hospital
Ankara, Turkey, 06500
United Kingdom
Addenbrookes Hospital
Cambridge, United Kingdom, CB2 0QQ
National Hospital for Neurology and Neurosurgery Queen Square
London, United Kingdom, NW3 2QG
The Royal Free Hospital
London, United Kingdom, NW3 2QG
Hope Hospital, Salford Royal NHS Foundation Trust
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
Amicus Therapeutics
Study Director: Medical Monitor Clinical Research Amicus Therapeutics

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Amicus Therapeutics Identifier: NCT01218659     History of Changes
Other Study ID Numbers: AT1001-012
First Posted: October 11, 2010    Key Record Dates
Last Update Posted: July 20, 2015
Last Verified: June 2015

Keywords provided by Amicus Therapeutics:
Fabry Disease

Additional relevant MeSH terms:
Fabry Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders